ALINE DE MOURA BRASIL MATOS

Índice h a partir de 2011
6
Projetos de Pesquisa
Unidades Organizacionais
LIM/52 - Laboratório de Virologia, Hospital das Clínicas, Faculdade de Medicina

Resultados de Busca

Agora exibindo 1 - 10 de 12
  • conferenceObject
    Neuroimaging profile in pediatric Neuromyelitis Optica Spectrum Disorders (NMOSD)
    (2017) PAOLILO, R.; RIMKUS, C. D. M.; PAZ, J. A.; APOSTOLOS-PEREIRA, S. L.; ARAUJO, A. L. P. C.; GOMES, A. B.; VENTURA, L. M. Gomes De Brito; PITOMBEIRA, M. S.; MATOS, A. D. M. B.; REED, U. C.; CALLEGARO, D.; SATO, D. K.
  • article 23 Citação(ões) na Scopus
    Prognostic indicators and outcomes of hospitalised COVID-19 patients with neurological disease: An individual patient data meta-analysis
    (2022) SINGH, Bhagteshwar; LANT, Suzannah; CIVIDINI, Sofia; CATTRALL, Jonathan W. S.; GOODWIN, Lynsey C.; BENJAMIN, Laura; MICHAEL, Benedict D.; KHAWAJA, Ayaz; MATOS, Aline de Moura Brasil; ALKERIDY, Walid; PILOTTO, Andrea; RAITH, Eamon; CHINTHAPALLI, Krishna; NORTLEY, Ross; PATERSON, Ross; CHANDRATHEVA, Arvind; WERRING, David J.; DERVISEVIC, Samir; HARKNESS, Kirsty; PINTO, Ashwin; JILLELLA, Dinesh; CONTINI, Erika; LOPEZ, Evelyn C.; BEACH, Scott; GUNASEKARAN, Kulothungan; SILVA, Ivan Rocha Ferreira Da; NALLEBALLE, Krishna; SANTORO, Jonathan; SCULLEN, Tyler; KAHN, Lora; KIM, Carla Y.; THAKUR, Kiran T.; CYSIQUE, Lucette; JAIN, Rajan; SARGENT, Brendan F.; UMAPATHI, Thirugnanam; NICHOLSON, Timothy R.; SEJVAR, James J.; HODEL, Eva Maria; SMITH, Catrin Tudur; SOLOMON, Tom; SOMASUNDARAN, Anushri; TAMBORSKA, Arina; ZHANG, Xin; WEBB, Glynn; YOUNAS, Komal; SAMI, Yaqub Al; BABU, Heavenna; BANKS, Tristan; CAVALLIERI, Francesco; COHEN, Matthew; DAVIES, Emma; DHAR, Shalley; MODOL, Anna Fajardo; MAGGI, Pietro; FAROOQ, Hamzah; HARTE, Jeffrey; HEY, Samuel; JOSEPH, Albert; KARTHIKAPPALLIL, Dileep; KASSAHUN, Daniel; LIPUNGA, Gareth; MASON, Rachel; MINTON, Thomas; MOND, Gabrielle; PESCH, Vincent van; POXON, Joseph; RABAS, Sophie; SOOTHILL, Germander; ZEDDE, Marialuisa; YENKOYAN, Konstantin; BREW, Bruce; LECHIEN, Jerome; SAUSSEZ, Sven; HEYSE, Alex; FERREIRA, Maria Lucia Brito; SOARES, Cristiane N.; CABREIRA, Veronica; ELICER, Isabel; BERNHARDI, Laura Eugenin-von; REYES, Waleng Nancupil; YIN, Rong; AZAB, Mohammed A.; ABD-ALLAH, Foad; ELKADY, Ahmed; ESCALARD, Simon; CORVOL, Jean-Christophe; DELORME, Cecile; VALDOLEIROS, Sofia R.; TATTEVIN, Pierre; BIGAUT, Kevin; LORENZ, Norbert; HORNUSS, Daniel; HOSP, Jonas; RIEG, Siegbert; WAGNER, Dirk; KNIER, Benjamin; LINGOR, Paul; WINKLER, Andrea Sylvia; OLIVEIRA, Vanessa; SHARIFI-RAZAVI, Athena; MOEIN, Shima T.; SEYEDALINAGHI, SeyedAhmad; JAMALIMOGHADAMSIAHKALI, Saeidreza; MORASSI, Mauro; PADOVANI, Alessandro; GIUNTA, Marcello; LIBRI, Ilenia; BERETTA, Simone; RAVAGLIA, Sabrina; KAIMOVSKY, Igor; FOSCHI, Matteo; CALABRESI, Paolo; PRIMIANO, Guido; SERVIDEI, Serenella; MERCURI, Nicola Biagio; LIGUORI, Claudio; PIERANTOZZI, Mariangela; SARMATI, Loredana; BOSO, Federica; GARAZZINO, Silvia; GUEKHT, Alla; MARIOTTO, Sara; PATRICK, Kimani N.; COSTACHE, Oana; PINCHERLE, Alexander; KLOK, Frederikus A.; MEZA, Roger; KOH, Jasmine; DIAZ, Eva Fernandez; BARRIOS-LOPEZ, Jose Maria; GUIJARRO-CASTRO, Cristina; BELTRAN-CORBELLINI, Alvaro; LAHIRI, Durjoy; MARTINEZ-POLES, Javier; DIEZMA-MARTIN, Alba Maria; MORALES-CASADO, Maria Isabel; GARCIA, Sergio Garcia; BREVILLE, Gautier; COEN, Matteo; UGINET, Marjolaine; BERNARD-VALNET, Raphael; PASQUIER, Renaud Du; KAYA, Yildiz; RAWLINSON, Rebecca; ABDELNOUR, Loay H.; RICE, Claire; MORRISON, Hamish; DEFRES, Sylviane; HUDA, Saif; ENRIGHT, Noelle; HASSELL, Jane; D'ANNA, Lucio; BENGER, Matthew; SZTRIHA, Laszlo; MHLANGA, Sithembinkosi
    Background Neurological COVID-19 disease has been reported widely, but published studies often lack information on neurological outcomes and prognostic risk factors. We aimed to describe the spectrum of neurological disease in hospitalised COVID-19 patients; characterise clinical outcomes; and investigate factors associated with a poor outcome. Methods We conducted an individual patient data (IPD) meta-analysis of hospitalised patients with neurological COVID-19 disease, using standard case definitions. We invited authors of studies from the first pandemic wave, plus clinicians in the Global COVID-Neuro Network with unpublished data, to contribute. We analysed features associated with poor outcome (moderate to severe disability or death, 3 to 6 on the modified Rankin Scale) using multivariable models. Results We included 83 studies (31 unpublished) providing IPD for 1979 patients with COVID-19 and acute new-onset neurological disease. Encephalopathy (978 [49%] patients) and cerebrovascular events (506 [26%]) were the most common diagnoses. Respiratory and systemic symptoms preceded neurological features in 93% of patients; one third developed neurological disease after hospital admission. A poor outcome was more common in patients with cerebrovascular events (76% [95% CI 67-82]), than encephalopathy (54% [42-65]). Intensive care use was high (38% [35-41]) overall, and also greater in the cerebrovascular patients. In the cerebrovascular, but not encephalopathic patients, risk factors for poor outcome included breathlessness on admission and elevated D-dimer. Overall, 30-day mortality was 30% [27-32]. The hazard of death was comparatively lower for patients in the WHO European region. Interpretation Neurological COVID-19 disease poses a considerable burden in terms of disease outcomes and use of hospital resources from prolonged intensive care and inpatient admission; preliminary data suggest these may differ according to WHO regions and country income levels. The different risk factors for encephalopathy and stroke suggest different disease mechanisms which may be amenable to intervention, especially in those who develop neurological symptoms after hospital admission.
  • conferenceObject
    MOG-IgA characterizes a subgroup of patients with central nervous system demyelination
    (2023) GOMES, Ana Beatriz Ayroza Galvao Ribeiro; KULSVEHAGEN, Laila; LIPPS, Patrick; CAGOL, Alessandro; FUERTES, Nuria Cerda; NEZIRAJ, Tradite; FLAMMER, Julia; LERNER, Jasmine; LECOURT, Anne-Catherine; SIEBENBORN, Nina de Oliveira S.; CORTESE, Rosa; SCHADELIN, Sabine; SCHOEPS, Vinicius; MATOS, Aline; MENDES, Natalia; PEREIRA, Clarissa dos Reis; MONTEIRO, Mario Luiz; PEREIRA, Samira Luisa Dos Apostolos; SCHINDLER, Patrick; CHIEN, Claudia; SCHWAKE, Carolin; SCHNEIDER, Ruth; PAKEERATHAN, Thivya; KIM, Ki Hoon; AKTAS, Orhan; FISCHER, Urs; MEHLING, Matthias; DERFUSS, Tobias; KAPPOS, Ludwig; AYZENBERG, Ilya; RINGELSTEIN, Marius; PAUL, Friedemann; CALLEGARO, Dagoberto; KIM, Ho Jin; KUHLE, Jens; PAPADOPOULOU, Athina; GRANZIERA, Cristina; PROBSTEL, Anne-Katrin
  • article 6 Citação(ões) na Scopus
    High proportion of Guillain-Barre syndrome associated with chikungunya in Northeast Brazil
    (2020) MATOS, Aline de Moura Brasil; CARVALHO, Fernanda Martins Maia; MALTA, Danielle Lima; RODRIGUES, Cleonisio Leite; FELIX, Alvina Clara; PANNUTI, Claudio Sergio; LIMA, Amanda Dias da Rocha; ESPOSITO, Danilo Lucas Alves; SANTOS, Leonilda Maria Barbosa dos; GLEHN, Felipe von; COLARES, Jeova Keny Baima; FONSECA, Benedito Antonio Lopes da; OLIVEIRA, Augusto Cesar Penalva de; ROMANO, Camila Malta
    From 2013 to 2015, sanitary authorities reported an increased incidence of Guillain-Barre syndrome (GBS) associated with Zika virus (ZIKV) in French Polynesia, Caribbean, and Brazil.(1-3) After the end of ZIKV epidemics, GBS cases where still above the usual limits in countries where the arrival of chikungunya virus (CHIKV) was also a concern.(3) Here, we report the findings from Hospital Geral de Fortaleza (HGF), a neuroinvasive arboviral disease vigilance center in Ceara State, Northeast Brazil.
  • article 12 Citação(ões) na Scopus
    Subacute Cognitive Impairment in Individuals With Mild and Moderate COVID-19: A Case Series
    (2021) MATOS, Aline de Moura Brasil; DAHY, Flavia Esper; MOURA, Joao Victor Luisi de; MARCUSSO, Rosa Maria Nascimento; GOMES, Andre Borges Ferreira; CARVALHO, Fernanda Martins Maia; FERNANDES, Gustavo Bruniera Peres; FELIX, Alvina Clara; SMID, Jerusa; VIDAL, Jose Ernesto; FROTA, Norberto Anizio Ferreira; CASSEB, Jorge; EASTON, Ava; SOLOMON, Tom; WITKIN, Steven S.; ROMANO, Camila Malta; OLIVEIRA, Augusto Cesar Penalva de
    Background: Previous reported neurologic sequelae associated with SARS-CoV-2 infection have mainly been confined to hospital-based patients in which viral detection was restricted to nasal/throat swabs or to IgM/IgG peripheral blood serology. Here we describe seven cases from Brazil of outpatients with previous mild or moderate COVID-19 who developed subacute cognitive disturbances. Methods: From June 1 to August 15, 2020, seven individuals 18 to 60 years old, with confirmed mild/moderate COVID-19 and findings consistent with encephalopathy who were observed >7 days after respiratory symptom initiation, were screened for cognitive dysfunction. Paired sera and CSF were tested for SARS-CoV-2 (IgA, IgG ELISA, and RT-PCR). Serum and intrathecal antibody dynamics were evaluated with oligoclonal bands and IgG index. Cognitive dysfunction was assessed by the Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), and the Clock Drawing Test (CDT). Results: All but one of our patients were female, and the mean age was 42.6 years. Neurologic symptoms were first reported a median of 16 days (IQR 15-33) after initial COVID-19 symptoms. All patients had headache and altered behavior. Cognitive dysfunction was observed mainly in phonemic verbal fluency (MoCA) with a median of six words/min (IQR 5.25-10.75) and altered visuospatial construction with a median of four points (IQR 4-9) (CDT). CSF pleocytosis was not detected, and only one patient was positive for SARS-Co Conclusions: A subacute cognitive syndrome suggestive of SARS-CoV-2-initiated damage to cortico-subcortical associative pathways that could not be attributed solely to inflammation and hypoxia was present in seven individuals with mild/moderate COVID-19.
  • article 6 Citação(ões) na Scopus
    Immunoglobulin A Antibodies Against Myelin Oligodendrocyte Glycoprotein in a Subgroup of Patients With Central Nervous System Demyelination
    (2023) GOMES, Ana Beatriz Ayroza Galvao Ribeiro; KULSVEHAGEN, Laila; LIPPS, Patrick; CAGOL, Alessandro; CERDA-FUERTES, Nuria; NEZIRAJ, Tradite; FLAMMER, Julia; LERNER, Jasmine; LECOURT, Anne-Catherine; SIEBENBORN, Nina De Oliveira S.; CORTESE, Rosa; SCHAEDELIN, Sabine; SCHOEPS, Vinicius Andreoli; MATOS, Aline de Moura Brasil; MENDES, Natalia Trombini; PEREIRA, Clarissa dos Reis; MONTEIRO, Mario Luiz Ribeiro; APOSTOLOS-PEREIRA, Samira Luisa dos; SCHINDLER, Patrick; CHIEN, Claudia; SCHWAKE, Carolin; SCHNEIDER, Ruth; PAKEERATHAN, Thivya; AKTAS, Orhan; FISCHER, Urs; MEHLING, Matthias; DERFUSS, Tobias; KAPPOS, Ludwig; AYZENBERG, Ilya; RINGELSTEIN, Marius; PAUL, Friedemann; CALLEGARO, Dagoberto; KUHLE, Jens; PAPADOPOULOU, Athina; GRANZIERA, Cristina; PROBSTEL, Anne-Katrin
    IMPORTANCE Differential diagnosis of patients with seronegative demyelinating central nervous system (CNS) disease is challenging. In this regard, evidence suggests that immunoglobulin (Ig) A plays a role in the pathogenesis of different autoimmune diseases. Yet little is known about the presence and clinical relevance of IgA antibodies against myelin oligodendrocyte glycoprotein (MOG) in CNS demyelination. OBJECTIVE To investigate the frequency of MOG-IgA and associated clinical features in patients with demyelinating CNS disease and healthy controls. DESIGN, SETTING, AND PARTICIPANTS This longitudinal study comprised 1 discovery and 1 confirmation cohort derived from 5 centers. Participants included patients with suspected or confirmed demyelinating diseases and healthy controls. MOG-IgA, MOG-IgG, and MOG-IgM were measured in serum samples and cerebrospinal fluid (CSF) of patients, who were assessed from September 2012 to April 2022. MAIN OUTCOMES AND MEASURES Frequency and clinical features of patients who were seropositive for MOG-IgA and double-seronegative for aquaporin 4 (AQP4) IgG and MOG-IgG. RESULTS After the exclusion of 5 participants with coexisting AQP4-IgG and MOG-IgA, MOG-IgG, and/or MOG-IgM, 1339 patients and 110 healthy controls were included; the median follow-up time was 39 months (range, 0-227 months). Of included patients with isolated MOG-IgA, 11 of 18 were female (61%), and the median age was 31.5 years (range, 3-76 years). Among patients double-seronegative for AQP4-IgG and MOG-IgG (1126/1339; 84%), isolated MOG-IgA was identified in 3 of 50 patients (6%) with neuromyelitis optica spectrum disorder, 5 of 228 patients (2%) with other CNS demyelinating diseases, and 10 of 848 patients (1%) with multiple sclerosis but in none of the healthy controls (0/110). The most common disease manifestation in patients seropositive for isolated MOG-IgA was myelitis (11/17 [65%]), followed by more frequent brainstem syndrome (7/16 [44%] vs 14/75 [19%], respectively; P =.048), and infrequent manifestation of optic neuritis (4/15 [27%] vs 46/73 [63%], respectively; P =.02) vs patients with MOG-IgG. Among patients fulfilling 2017 McDonald criteria for multiple sclerosis, MOG-IgA was associated with less frequent CSF-specific oligoclonal bands (4/9 [44%] vs 325/351 [93%], respectively; P <.001) vs patients with multiple sclerosis who were MOG-IgG/IgA seronegative. Further, most patients with isolated MOG-IgA presented clinical attacks after recent infection or vaccination (7/11 [64%]). CONCLUSION AND RELEVANCE In this study, MOG-specific IgA was identified in a subgroup of patients who were double-seronegative for AQP4-/MOG-IgG, suggesting that MOG-IgA may be a novel diagnostic biomarker for patients with CNS demyelination.
  • conferenceObject
    Five-year follow-up of pediatric onset Neuromyelitis Optica Spectrum Disorders (NMOSD)
    (2017) PAOLILO, R. B.; PAZ, J. A.; APOSTOLOS-PEREIRA, S. L.; RIMKUS, C. D. M.; ARAUJO, A. L. P. C.; VENTURA, L. M. G. D. B.; PITOMBEIRA, M. S.; GOMES, A. B.; MATOS, A. D. M. B.; TORRETTA, P. H. B.; REED, U. C.; CALLEGARO, D.; SATO, D. K.
  • article 15 Citação(ões) na Scopus
    Dichotomy in Fatal Outcomes in a Large Cohort of People Living with HTLV-1 in Sao Paulo, Brazil
    (2020) MARCUSSO, Rosa Maria N.; WEYENBERGH, Johan Van; MOURA, Joao Victor Luisi de; DAHY, Flavia Esper; MATOS, Aline de Moura Brasil; HAZIOT, Michel E. J.; VIDAL, Jose E.; FONSECA, Luiz Augusto M.; SMID, Jerusa; ASSONE, Tatiane; CASSEB, Jorge; OLIVEIRA, Augusto Cesar Penalva de
    Background: Despite its relatively low incidence of associated diseases, Human T-cell Leukemia Virus-1 (HTLV-1) infection was reported to carry a significant risk of mortality in several endemic areas. HTLV-1-associated diseases, adult T-cell leukemia /lymphoma (ATLL) and HTLV-1-associated myelopathy/tropical spastic paraperesis (HAM/TSP), as well as frequent coinfections with human immunodeficiency virus (HIV), hepatitis C virus (HCV), and Strongyloides stercoralis were associated to increased morbidity and mortality of HTLV-1 infection. Objective: To determine the mortality rate and its associated variables from an open cohort started in July 1997 at the HTLV Clinic, Emilio Ribas Institute (IIER), a major infectious disease hospital in Sao Paulo, Brazil. Methods: Since inception up to September 2018, we admitted 727 HTLV-1-infected individuals, with a rate of 30-50 new admissions per year. All patient data, including clinical and laboratory data, were regularly updated throughout the 21-year period, using a dedicated REDCap database. The Ethical Board of IIER approved the protocol. Results: During 21 years of clinical care to people living with HTLV-1 in the Sao Paulo region, we recruited 479 asymptomatic HTLV-1-infected individuals and 248 HAM/TSP patients, of which 632 remained under active follow-up. During a total of 3800 person-years of follow-up (maximum follow-up 21.5 years, mean follow-up 6.0 years), 27 individuals died (median age of 51.5 years), of which 12 were asymptomatic, one ATLL patient and 14 HAM/TSP patients. HAM/TSP diagnosis (but neither age nor gender) was a significant predictor of increased mortality by univariate and multivariate (hazard ratio (HR) 5.03, 95% CI [1.96-12.91], p = 0.001) Cox regression models. Coinfection with HIV/HCV was an independent predictor of increased mortality (HR 15.08; 95% CI [5.50-41.32]; p < 0.001), with AIDS-related infections as a more frequent cause of death in asymptomatics (6/13; p = 0.033). HIV/HCV-negative fatal HAM/TSP cases were all female, with urinary tract infection and decubitus ulcer-associated sepsis as the main cause of death (8/14, p = 0.002). Conclusions: All-cause mortality among people living with HTLV-1 in Sao Paulo differs between asymptomatic (2.9%) and HAM/TSP patients (7.3%), independent of age and gender. We observe a dichotomy in fatal cases, with HAM/TSP and HIV/HCV coinfection as independent risk factors for death. Our findings reveal an urgent need for public health actions, as the major causes of death, infections secondary to decubitus ulcers, and immune deficiency syndrome (AIDS)-related infections, can be targeted by preventive measures.
  • conferenceObject
    retinal changes in patients with immunoglobulin a antibodies against myelin oligodendrocyte glycoprotein
    (2023) FUERTES, Nuria Cerda; BEATRIZ, Ayroza Galvao Ribeiro Gomes Ana; KULSVEHAGEN, Laila; LIPPS, Patrick; NEZIRAJ, Tradite; FLAMMER, Julia; LERNER, Jasmine; LECOURT, Anne-Catherine; PEREIRA, Clarissa dos Reis; MONTEIRO, Mario Luiz; SCHINDLER, Patrick; SCHOEPS, Vinicius Andreoli; MATOS, Aline; MENDES, Natalia; SCHWAKE, Carolin; PAKEERATHAN, Thivya; AKTAS, Orhan; FISCHER, Urs; DERFUSS, Tobias; KAPPOS, Ludwig; AYZENBERG, Ilya; RINGELSTEIN, Marius; PAUL, Friedemann; CALLEGARO, Dagoberto; GRANZIERA, Cristina; KUHLE, Jens; PROBSTEL, Anne-Katrin; PAPADOPOULOU, Athina
  • conferenceObject
    Case series: a specialty center 10 year experience with use of azathioprine in neuromielytis optica spectrum disorders (NMOSD)
    (2017) GOMES, A. B. A. G. R.; MATOS, A. de Moura Brasil; VENTURA, L. M. Gomes de Brito; PITOMBEIRA, M. Sales; PAOLILO, R. Barbosa; TORRETTA, P. H. Bruel; JORGE, F. Menucci de Haidar; SATO, D. Kazutoshi; CALLEGARO, D.; PEREIRA, S. L. Apostolos